echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > TUKYSA (tucatinib) has been approved in Australia for the treatment of metastasis HER2-positive breast cancer.

    TUKYSA (tucatinib) has been approved in Australia for the treatment of metastasis HER2-positive breast cancer.

    • Last Update: 2020-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Seattle Genetics announced today that Australian regulators have approved TUKYSA® (tucatinib) to be used in the treatment of advanced non-removable or metastasis HER2-positive breast cancer patients, including those with brain metastasis.
    Australia has joined the United States, Switzerland, Canada and Singapore in forming Project Orbis, an initiative of the U.S. Food and Drug Administration's Center of Excellence in Oncology to promote simultaneous review of anti-tumor drugs by international regulators.
    , TUKYSA became the first new drug Obis plans to approve in the United States and is currently under review in the European Union.
    Clay Siegall, Executive Director of Genetics, Seattle, said, "Orbis' planned global review of TUKYSA will bring this new treatment to market quickly, and we look forward to bringing TUKYSA to patients around the world."
    the approval was based on the results of a key trial, HER2CLIMB (double-blind placebo-controlled trial), which recruited 612 patients who had previously been treated with treatments such as curto-bead monotherapy and parto-pearl monoantigen, respectively.
    findings were published in the New England Journal of Medicine in December 2019.
    TUKYSA is an oral drug that is a tyrosine kinase inhibitor of the HER2 protein.
    in-body trials, TUKYSA inhibited phosphorylation of HER2 and HER3, thereby inhibiting downstream MAPK and AKT signaling and cell proliferation, and showing anti-tumor activity in tumor cells expressing HER2.
    in vivo tests, TUKYSA inhibited the growth of HER2-positive tumors.
    combination of TUKYSA and anti-HER2 antibody crater bead monoantigens showed enhanced anti-tumor activity both in vitro and in vivo.
    in the United States, TUKYSA's combination with curtum monoantigen and carpedabin was approved for advanced non-excisive or metastasis adult patients with HER2-positive breast cancer, including those with brain metastasis.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.